Luxury UK car makers hit by ‘multiple geopolitical headwinds'
Luxury, high-performance and niche UK car makers face challenges which 'threaten competitiveness and growth', according to a report.
The Society of Motor Manufacturers and Traders (SMMT) said companies such as Aston Martin, McLaren and Morgan are having to cope with volatile trading conditions, decarbonisation rules and production cost pressures.
The study found the total turnover of the UK's high-value, small-volume manufacturers in 2024 was more than £5.5 billion, with around nine in 10 of their vehicles shipped overseas.
They were responsible for just 4% of the UK's car production, but accounted for 12% of its value.
In excess of 15,000 people are employed in high-skilled, well-paid jobs by the companies, the SMMT found.
The report stated: 'The UK's small volume manufacturers face a series of challenges … (which) threaten competitiveness and growth.'
SMMT chief executive Mike Hawes said: 'Britain's luxury, performance and niche vehicle makers are exemplars of automotive design, engineering and manufacturing – and a quintessential British success story.
'Government rightly recognises the importance of these high-value and iconic brands to the UK economy and, amid multiple geopolitical headwinds, the industry is looking to work together to ensure the sector can not just survive but thrive.
'A successful sector would deliver the economic growth, well-paid jobs and exports that Government craves, helping keep Britain firmly on the global automotive map.'
Industry minister Sarah Jones, said: 'Our luxury automotive manufacturers are iconic British brands recognised worldwide, and this report rightly highlights the huge contribution they make to the UK economy.
'We're ensuring our carmakers go from strength to strength as we deliver our Plan for Change, and we've already secured landmark trade deals with the US and India, which will cut tariffs for the sector and create new export opportunities.
'Our modern industrial strategy will set out a long-term plan to support our manufacturers, including by creating the right conditions for increased investment, bringing growth, jobs and opportunities to every part of the UK.'
The UK-US trade deal was confirmed in a call between Prime Minister Sir Keir Starmer and US President Donald Trump on May 8.
It included American tariffs on UK cars being 10% for the first 100,000 vehicles exported.
Mr Trump had previously set the tariff rate on car exports to the US at 27.5%.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
20 minutes ago
- Bloomberg
What to Expect From Reeves' UK Spending Review
00:00 James, what can we expect then from this spending review for the chancellor. A crucial day for her and her team. What are you going to be scrutinizing? I mean, the reason it's crucial is this is a fifth of the UK economy in size 600 billion a year. We know that 200 billion is going to be the NHS, 39 billion defence. 94 in education, what is happening to the rest and also what is happening to the 134 billion they've put aside for capital investment? Of that we expect to see some go to housing roughly 40 billion and some get around investment. They've announced that 15 billion. This is the moment that Rachel Reeves says I was elected a Labour chancellor to do X and we find out what X is today and they're going to lean in. The expectations are they will lean in to that £134 billion, I should say, capital expenditures plan. That's the kind of headline they want to be pushing. What what is this going to mean for that for the chancellor who's seen the ratings in terms of the polls, not just for her, but the prime minister as well plummet on some of these decisions? Is this kind of a break, a make or break moment for the chancellor? How decisive is this moment going to be for that for the head of the UK Treasury? The way I would explain it is today we are casting a political die as the government, not the polls, not the politics, but the economics. The cold, hard cash. The shape of the next election will be decided today. The last spending review was done in Covid by Rishi Sunak, the one before that was 2015 pre Brexit. That's the kind of size of the event we are talking about today. And like you say, this could be the comeback moment for the Chancellor. Where growth comes from, this investment comes from this private sector is rejuvenated from this. It could also be the moment we find some quite difficult cuts and we find out about very tough decisions the UK Government will have to take in the years going forward.
Yahoo
25 minutes ago
- Yahoo
Those who invested in Momentum Group (JSE:MTM) three years ago are up 188%
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But if you buy shares in a really great company, you can more than double your money. For example, the Momentum Group Limited (JSE:MTM) share price has soared 140% in the last three years. How nice for those who held the stock! On top of that, the share price is up 27% in about a quarter. But this could be related to the strong market, which is up 11% in the last three months. Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. Momentum Group was able to grow its EPS at 181% per year over three years, sending the share price higher. This EPS growth is higher than the 34% average annual increase in the share price. So one could reasonably conclude that the market has cooled on the stock. This cautious sentiment is reflected in its (fairly low) P/E ratio of 9.66. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image). It is of course excellent to see how Momentum Group has grown profits over the years, but the future is more important for shareholders. Take a more thorough look at Momentum Group's financial health with this free report on its balance sheet. When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. As it happens, Momentum Group's TSR for the last 3 years was 188%, which exceeds the share price return mentioned earlier. The dividends paid by the company have thusly boosted the total shareholder return. It's nice to see that Momentum Group shareholders have received a total shareholder return of 77% over the last year. And that does include the dividend. That gain is better than the annual TSR over five years, which is 20%. Therefore it seems like sentiment around the company has been positive lately. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. It's always interesting to track share price performance over the longer term. But to understand Momentum Group better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Momentum Group , and understanding them should be part of your investment process. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on South African exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
29 minutes ago
- Yahoo
ONWARD Medical Schedules Webcast to Provide Q1 2025 Business Update and Year-To-Date Highlights
EINDHOVEN, the Netherlands, June 11, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury and other movement disabilities, today announces that it will host a webcast to discuss its Q1 2025 business update and year-to-date highlights. The webcast will be held on June 17, 2025, at 2:00PM CET / 08:00AM ET. It will be hosted by CEO Dave Marver. To join the session, please register using this link. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury (SCI) and other movement disabilities. Building on more than a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA). The Company's ARC-EX® System is cleared for commercial sale in the US. In addition, the Company is developing an investigational implantable system called ARC-IM® with and without an implanted brain-computer interface (BCI). Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). To learn more about ONWARD Medical's commitment to partnering with the spinal cord injury community to develop innovative solutions for restoring movement, function, and independence after spinal cord injury, please visit To be kept informed about the Company's technologies, research studies, and the availability of therapies in your area, please complete this webform. For Media Inquiries: Sébastien Cros, VP Communications media@ For Investor Inquiries: investors@ Disclaimer Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Trademarks: ONWARD, ARC-EX, ARC-IM, ARC-BCI, and the stylized O-Logo are proprietary and registered trademarks of ONWARD Medical. Unauthorized use is strictly prohibited. ARC-EX Indication for Use (US): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive). Other Investigational Products: All other ONWARD Medical devices and therapies including ARC-IM and ARC-BCI are investigational and not available for commercial use.
